Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
1995-06-06
2008-09-23
Duffy, Patricia A. (Department: 1645)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C800S003000
Reexamination Certificate
active
07427392
ABSTRACT:
This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-β peptide (x−≧41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both Aβ(x−≧41) and tau. Low levels of Aβ(x−≧41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of Aβ(x−≧41) and low levels of tau are a negative indication of Alzheimer's disease.
REFERENCES:
patent: 4271140 (1981-06-01), Bunting
patent: 4474892 (1984-10-01), Murad et al.
patent: 4666829 (1987-05-01), Glenner et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5547841 (1996-08-01), Marotta et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5612486 (1997-03-01), McConlogue et al.
patent: 5750349 (1998-05-01), Suzuki et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5837672 (1998-11-01), Schenk et al.
patent: 6114133 (2000-09-01), Seubert et al.
patent: 6284221 (2001-09-01), Schenk et al.
patent: 6610493 (2003-08-01), Citron et al.
patent: 2003/0148392 (2003-08-01), Citron et al.
patent: 2004/0253643 (2004-12-01), Seubert et al.
patent: 2004/0265920 (2004-12-01), Seubert et al.
patent: 2005/0069968 (2005-03-01), Seubert et al.
patent: 705907 (1999-09-01), None
patent: 2205359 (2006-07-01), None
patent: 0 444 856 (1991-09-01), None
patent: 0 683 234 (1995-11-01), None
patent: 0-683-234 (1995-11-01), None
patent: 0 667 959 (2003-08-01), None
patent: 0 792 458 (2004-10-01), None
patent: WO 90/12870 (1990-11-01), None
patent: WO 90/12871 (1990-11-01), None
patent: WO 93/14200 (1993-07-01), None
patent: WO 94/10569 (1994-05-01), None
patent: WO 96/15452 (1996-05-01), None
patent: WO 96/25435 (1996-08-01), None
patent: WO 97/048983 (1997-12-01), None
patent: WO 01/62284 (2001-08-01), None
Games etal, Nature, 373:523-527, Feb. 9, 1995.
Vigo-Pelfrey, Journal of Neurochemistry, 61:1965-1968, 1993.
Iwatsubo et al, Neuron, 13:45-53, Jul. 1994.
Seubert et al, Nature., 359:325-327, Sep. 24, 1992.
Aukuchi etal, Annals of the New York Academy of Sciences, 695:217-223, 1993.
Uno et al, Annals of the New York Academy of Sciences, 695:232-235, 1993.
Lannfelt etal, Behavorial Brain Research, 57:203-213, 1993.
Suzuki etal, Science, 164:1337-1340, May 27, 1994.
Fukuchi et al Annals of the New York Academy of Sciences, 1992 pp. 217-223.
Felenstein etal. in Alzheimer's and Parkinson's Diseases, I. Hanin ed. Plenum Press, Ny, p. 406 col. 1, 1995.
Lanfelt etal, Behav. Brain. Res. 57, all pages, 1993.
C. Vigo-Pelfrey et al. (1994)Society for Neuroscience Abstractsvol. 20 #191.2 Detection of Aβ1-42In CSF And Various Cell Conditioned Media.
K. Urakami et al. (1992)Acta Neurol Scand85:343-346. Amyloid βprotein precursors with kunitz-type inhibitor domains and acetyl-cholinesterase in cerebrospinal fluid from patients with demential of the Alzheimer type.
R. Prior et al. (1991)Neuroscience Letters124:69-73. Quantitative changes in the amyloid βA4 precursor protein in Alzheimer cerebrospinal fluid.
B. McDonald et al. (1988)Alzheimer Disease and Associated Disorders2(3):186. The Characterisation And Purification Of A Protein Present In Cerebrospinal Fluid And Serum, Using A Monoclonal Antibody Which Reacts Immunohistochemically With Amyloid Deposits In Alzheimer Brains.
D. Allsop (1986)Neuroscience Letters68:252-256. Monoclonal Antibodies Raised Against A Subsequence Of Senile Plaque Core Protein React With Plaque Cores, Plaque Periphery And Cerebrovascular Amyloid In Alzheimer's Disease.
T. Ishii (1986)Neuropathology and Applied Neurobiology12:441-445. A Monoclonal Antibody To Amyloid In The Brains Of Patients With Alzheimer's Disease.
Haass et al. (1992)Nature359:322-325. Amyloid β-peptide is produced by cultured cells during normal metabolism.
Wolozin et al. (1987)Annals of Neurology22(4):521-526. Alzheimer-Related Neuronal Protein A68: Specificity and Distribution.
Ueda et al. (1990)The Journal of Neuroscience10(10):3295-3304. Alz-50 Recognizes a Phosphorylated Epitope of Tau Protein.
Chui et al. (1993)Arch Neurol50:57-63. Reliability and Usefulness of a New Immunochemical Assay for Alzheimer's Disease.
van Gool and Bolhuis, “Cerebrospinal Fluid Markers of Alzheimer's Disease”,JAGS, 39:1025-1039 (1991).
Scheuner, D. et al., “Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.” Nature Medicine, Aug. 1996, vol. 2, No. 8, pp. 864-870.
Spitzer, Chair, Work Group to Revise DSM-III, Diagnostic and Statistical Manual of Mental Disorders (Third Edition-Revised), 1987, 119-121 American Psychiatric Association, Washington, D.C.
Glenner and Wong (1984) Biochem. Biophys. Res. Commun. 120:885-890. Alzheimer's Disease: Inital Report Of The Purification And Characterization Of A Novel Cerebrovascular Amyloid Protein.
Kang et al. (1987) Nature 325:733-736. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor.
Roher et al. (1993) Proc. Natl. Acad. Sci. USA 90:1086-840. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease.
Iwatsubo et al. (1994) Neuron 13:45-53. Visualization of Aβ42 (43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42 (43).
Selkoe (1994) J. Neuropath. and Exp. Neurol. 53:438-447. Alzheimer's Disease: A Central Role for Amlyoid.
Selkoe (1991) Neuron 6:487. The Molecular Pathology of Alzheimer's Disease.
Goate et al. (1991) Nature 349:704-706. Segration of a missense mutation in the amlyoid precursor protein gene with familial Alzheimer's disease.
Chartier Harlan et al. (1991) Nature 353:844-846. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene.
Murrell et al. (1991) Science 254:97-99. A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease.
Suzuki et al. (1994) Science 264:1336-1340. An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βAPP717) Mutants.
Mullan et al. (1992) Nature Genet 1:345-347. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid.
Glenner and Wong (1984) Biochem. Biophys. Res. Commun. 122:1131-1135. Alzheimer's Disease And Down's Syndrome: Sharing Of A Unique Cerebrovascular Amyloid Fibril Protein.
Masters et al. (1985) Proc. Natl. Acad. Sci USA 82:4245-4249. Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Selkoe et al. (1986) J. Neurochem. 46:1820-1834. Isolation of Low-Molecular-Weight Proteins from Amyloid Plaque Fibers in Alzheimer'Diease.
Joachim et al. (1988) Brain Research 474:100-111. Protein chemical and immunocytochemical studies of meningovascular β-amyloid protein in Alzheimer's disease and normal aging.
Hilbich et al. (1991) J. Mol. Biol. 218:149-163. Aggregation and Secondary Structure of Synthetic Amyloid βA4 Peptides of Alzheimer's Disease.
Barrow and Zagorski (1991) Science 253:179-182. Solution Structures of β Peptide and Its Constituent Fragments: Relation to Amyloid Deposition.
Burdick et al. (1992) J. Biol. Chem. 267:546-554. Assembly and Aggregation Properties of Synthetic Alzheimer's A4/β Amyloid Peptide Analogs.
Palmert et al. (1989) Proc. Natl. Acad. Sci. USA 86:6338-6342. The β-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid.
Weidemann et al. (1989) Cell 57:115-126. Identification, Biogenesis, and Locali
Barbour Robin
Schenk Dale B.
Seubert Peter A.
Vigo-Pelfrey Carmen
Duffy Patricia A.
Elan Pharmaceuticals Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Methods for aiding in the diagnosis of alzheimer's disease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for aiding in the diagnosis of alzheimer's disease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for aiding in the diagnosis of alzheimer's disease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3982089